Trial Profile
A study of OTL38 for detecting pulmonary ground-glass opacities
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Apr 2018
Price :
$35
*
At a glance
- Drugs Folate-fluorescein isothiocyanate conjugate (Primary)
- Indications Breast cancer; Lung cancer; Ovarian cancer; Pituitary cancer; Primary hyperparathyroidism; Renal cell carcinoma
- Focus Adverse reactions; Diagnostic use
- 11 Apr 2018 New trial record
- 04 Apr 2018 Results published in the Journal of Thoracic Oncology